Global digital therapeutics market set to grow from USD 6.08 billion to USD 73.09 billion by 2033

From GlobeNewswire: 2024-06-26 22:00:00

The global digital therapeutics market is set to grow from USD 6.08 billion in 2023 to USD 73.09 billion by 2033, at a CAGR of 28.23%. DTx uses software to provide evidence-based treatments for various medical conditions like diabetes and mental illness. The market is driven by the rise in chronic illnesses and the need for innovative healthcare solutions. The software & services segment holds the largest revenue share in the market, with a focus on using AI and ML technologies.

In the digital therapeutics market, the treatment segment dominates with a focus on providing solutions for chronic conditions like diabetes and mental health disorders. The business to customer sales channel is expected to grow at the highest CAGR during the projected timeframe, driven by increased awareness and demand for easily accessible healthcare solutions. North America holds the largest share of the market, while Asia Pacific is predicted to grow at the fastest pace due to high demand for IT services.

Key players in the global digital therapeutics market include LifeScan Inc., Teladoc Health, Omada Health Inc., and Pear Therapeutics, among others. Recent developments include Lupin’s release of LYFE, an evidence-based heart care program in India. The market is segmented by type, application, and sales channel, with projected growth in regions like North America, Europe, and Asia Pacific. The use of digital therapeutics is expected to revolutionize the healthcare industry and improve patient outcomes globally.



Read more at GlobeNewswire: Global Digital Therapeutics Market Size To Worth USD 73.09